While AO exon skipping clinical trials appear promising for DMD17, 18, 20, 41, 42, the high incidence of cardiomyopathy in these patients, with associated high levels of mortality, indicate that restoring dystrophin protein in heart to modulate the cardiac phenotype is of high priority. This evidence concerns the gene DMD and cardiomyopathy.